CD8A and neoplasm: In another and larger TMA-based study, tumoral expression of programmed death ligand 1 (PD-L1) or PD-L1 plus tumor infiltrating CD8+ T-cells were correlated to significantly shorter PFS and overall survival (OS) in patients treated with sunitinib or pazopanib [10].